Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NASDAQ: RVPH · Real-Time Price · USD
1.150
-0.060 (-4.96%)
Oct 8, 2024, 3:00 PM EDT - Market open
-4.96%
Market Cap 38.06M
Revenue (ttm) n/a
Net Income (ttm) -35.99M
Shares Out 33.09M
EPS (ttm) -1.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,665
Open 1.230
Previous Close 1.210
Day's Range 1.140 - 1.231
52-Week Range 0.600 - 6.800
Beta -0.09
Analysts Strong Buy
Price Target 14.50 (+1,160.87%)
Earnings Date Nov 12, 2024

About RVPH

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptom... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 15
Stock Exchange NASDAQ
Ticker Symbol RVPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for RVPH stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 1,160.87% from the latest price.

Price Target
$14.5
(1,160.87% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

7 hours ago - GlobeNewsWire

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

6 days ago - GlobeNewsWire

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

6 weeks ago - GlobeNewsWire

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary d...

3 months ago - GlobeNewsWire

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek...

4 months ago - GlobeNewsWire

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek...

4 months ago - GlobeNewsWire

Reviva to Participate in the BIO International Convention

CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek...

5 months ago - GlobeNewsWire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – ...

5 months ago - GlobeNewsWire

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia –

5 months ago - GlobeNewsWire

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek...

5 months ago - GlobeNewsWire

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek...

5 months ago - GlobeNewsWire

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) f...

6 months ago - GlobeNewsWire

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia –

6 months ago - GlobeNewsWire

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...

6 months ago - GlobeNewsWire

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...

7 months ago - GlobeNewsWire

Reviva to Present at the UBS Virtual CNS Day

CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...

7 months ago - GlobeNewsWire

Reviva to Present at the 36th Annual ROTH Conference

CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...

7 months ago - GlobeNewsWire

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

8 months ago - GlobeNewsWire

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Virtual event on Thursday, February 15, 2024 at 12:00 PM ET will feature KOLs Larry Ereshefsky, PharmD, BCPP, FCCP, of Follow the Molecule and Mark Opler, PhD, MPH of WCG Virtual event on Thursday, Fe...

8 months ago - GlobeNewsWire

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek...

9 months ago - GlobeNewsWire

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to a...

9 months ago - Accesswire

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data supp...

9 months ago - GlobeNewsWire

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

CUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

10 months ago - GlobeNewsWire

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

11 months ago - GlobeNewsWire

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...

11 months ago - GlobeNewsWire